Methods and compositions for treatment of epileptic disorders
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
1. A method of treating PCDH19 related epilepsy comprising administering to a patient in need thereof a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof twice daily.
3. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
4. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof in an amount of up to 1,800 mg/day.
5. The method of claim 1 , wherein the pharmaceutical composition is an oral capsule.
6. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension.
7. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof and is administered three times daily.
9. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof administered three times daily wherein the patient is administered an amount of up to 1,800 mg/day.
10. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
12. The method of claim 1 , wherein the patient is administered 50 mg ganaxolone or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the patient is administered 100 mg ganaxolone or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the patient is administered 200 mg ganaxolone or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the patient is administered 300 mg ganaxolone or a pharmaceutically acceptable salt thereof.
16. The method of claim 1 , wherein the patient is administered 400 mg ganaxolone or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein the patient is administered 500 mg ganaxolone or a pharmaceutically acceptable salt thereof.
18. The method of claim 1 , wherein the patient is administered oral capsules comprising 200-600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
19. The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures.
20. The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures, the severity of seizures, or a combination thereof.